Adial Pharmaceuticals (ADIL) said Thursday it has received a notice of allowance from the US Patent and Trademark Office for a new patent covering additional genotype combinations identified through its genetic diagnostic tool.
The company said that once issued, the patent will expand its intellectual property protection around AD04, its lead investigational drug that aims to treat alcohol use disorder.
Adial shares were down more than 6% in recent trading.
Price: 0.97, Change: -0.07, Percent Change: -6.31
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments